General Mills (GIS)
(Delayed Data from NYSE)
$65.99 USD
-2.32 (-3.40%)
Updated Nov 6, 2024 04:00 PM ET
After-Market: $65.98 -0.01 (-0.02%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth B Momentum B VGM
Price, Consensus and EPS Surprise
GIS 65.99 -2.32(-3.40%)
Will GIS be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for GIS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for GIS
Campbell Soup's Strategies Stir Up Growth Amid Market Challenges
Flowers Foods' Focus on Branded Retail & Innovation to Drive Growth
GIS: What are Zacks experts saying now?
Zacks Private Portfolio Services
General Mills Rallies 18% in 3 Months: Buy, Hold or Sell GIS Stock?
Time to Buy General Mills Stock After Beating Earnings Expectations?
Company News for Sep 19, 2024
Other News for GIS
Notable companies reporting after market close
Gilead Sciences Shows Strong Q3 Results Amid Strategic Initiatives
Gilead Sciences: Strong Financial Performance and Promising Outlook Underpin Buy Rating
Closing Bell Movers: AppLoving up 29% after Q3 earnings beat
Hold Rating for Gilead Sciences Amid Promising Yet Preliminary Anito-cel Trial Results